Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Entheon Biomedical

ENTBFOTCQB

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.2200

-0.00600-2.65%

At close: -

$0.00700

-0.21-96.82%

After Hours: Feb 14, 8:40 AM EDT

Entheon Biomedical (ENTBF) Forecast

News

Earnings Entheon Biomedical (ENTBF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Entheon Biomedical (OTC:ENTBF) Stock

Entheon Biomedical Stock (OTC: ENTBF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, August 30, 2022

World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
Lara Goldstein

Wednesday, June 15, 2022

Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Natan Ponieman

Tuesday, June 07, 2022

Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Lara Goldstein

Wednesday, June 01, 2022

Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Lara Goldstein

Tuesday, April 05, 2022

Entheon Biomedical Announces Non-Brokered Private Placement Financing
Fermin Orgambide

Wednesday, February 09, 2022

Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
Benzinga Cannabis

Monday, February 07, 2022

Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins
Natan Ponieman

Thursday, February 03, 2022

Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
Natan Ponieman

Monday, December 13, 2021

Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments
Rachael Green - Sponsored

Monday, October 18, 2021

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman

Wednesday, October 13, 2021

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman

Wednesday, October 06, 2021

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics
Rachael Green - Sponsored

Wednesday, August 11, 2021

What Do You Really Know About Psychedelics And Psychedelics Stocks?
Jeff Siegel

Tuesday, August 03, 2021

Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
Natan Ponieman

Monday, August 02, 2021

Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
Natan Ponieman
89bio Says Completed Target Enrollment In His...
Benzinga Newsdesk

Friday, July 30, 2021

Entheon Biomedical Corp. Strengthens Its Psychedelic-Assisted Protocols Through Acquisition Of Lobo Genetics
Jelena Martinovic

Monday, June 21, 2021

Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Natan Ponieman

Thursday, May 06, 2021

Video: The Psychedelics Market With Entheon Biomedical, MagicMed, Natan Ponieman
Jose Rodrigo Safdiye

Tuesday, March 30, 2021

Why Would Anyone Invest In The Psychedelics Medicine Market?   
Jeff Siegel

Friday, March 26, 2021

Highlights From Day 2 Of Benzinga's Biotech Small Cap Conference
Shanthi Rexaline

Wednesday, January 27, 2021

First Psychedelics ETF Debuts On NEO Exchange
Natan Ponieman

Tuesday, January 05, 2021

Why The Psychedelics Market Is NOT Cannabis 2.0
Jeff Siegel

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved